Don't Delay Urgent Treatment of Early-Onset Severe Toxicity or Overdose of 5-FU and Capecitabine

TUESDAY, OCTOBER 1, 2019
12:00 pm – 1:15 pm
Salon G
Hilton Austin
Austin, Texas
Lunch will be provided.

FACULTY
Anne Engelhart, AGPCNP-BC
Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

OBJECTIVES
  • Outline the causes of 5-FU and capecitabine overdoses and early-onset severe toxicity
  • Recognize "red flags" of 5-FU and capecitabine early-onset severe toxicity and overdose
  • Explore cases of cardiotoxicity and other forms of early-onset severe toxicity
  • Summarize evidence supporting VISTOGARD® (uridine triacetate) as an emergency treatment for 5-FU or capecitabine early-onset severe toxicity or overdose
  • Review VISTOGARD® administration and limitations of use
  • Educate patients and caregivers about 5-FU and capecitabine early-onset severe toxicity and overdose

Please confirm you will attend by submitting the information below.
You will receive an email confirming your registration.




Female
Male


CONTACT INFORMATION


PROFESSIONAL INFORMATION


ADDITIONAL INFORMATION

Wellstat Therapeutics Logo

Please contact Shiva Noorchashm at registration@WELLSTATevent.com
with any questions regarding this symposium.

The Company recognizes the sensitive nature of the information that may be disclosed on this form, and is committed to
keeping such information confidential. Therefore, we will not disclose any of the information on this form to anyone other
than the sponsor of this meeting and affiliates who have a reasonable business need to have access to such information.